Latin America Ploughs Ahead With Joint Pricing Strategy
This article was originally published in Scrip
Executive Summary
Pharmaceutical companies wanting to sell high-cost drugs in Latin America may find themselves talking with multiple countries at once to find a single acceptable price. Mercosur member and associate countries are wielding their collective might to secure lower prices through a new negotiation mechanism supported by the Pan American Health Organization / World Health Organization. Mercosur health ministers have already announced an offer from Gilead to supply its hepatitis C drug Sovaldi (sofosbuvir) and next up for discussion are likely to be costly cancer medicines.
You may also be interested in...
Lessons From Mercosur Multi-Country Pricing Negotiations
Latin American joint price negotiations have proved successful and other countries are taking note.
South American Pricing Coalition Sets Sights On Alexion’s Soliris and Monoclonal Antibodies
A South American pricing coalition that includes Brazil, Venezuela and Argentina has announced plans to buy high-cost drugs, such as eculizumab (Alexion’s Soliris).
Brazil Authorizes Oxford/AZ and Sinovac Vaccines
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
Need a specific report? 1000+ reports available
Buy Reports